Holen Sie sich die Stockscreener-App
23.76
0.68%
0.16
Handel nachbörslich:
23.77
0.010
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$23.60
Offen:
$23.73
24-Stunden-Volumen:
33.36M
Relative Volume:
0.79
Marktkapitalisierung:
$135.09B
Einnahmen:
$63.83B
Nettoeinkommen (Verlust:
$10.77B
KGV:
12.64
EPS:
1.88
Netto-Cashflow:
$12.44B
1W Leistung:
-1.12%
1M Leistung:
-4.65%
6M Leistung:
-5.75%
1J Leistung:
-17.98%
1-Tages-Spanne:
$23.61
$23.81
1-Wochen-Bereich:
$23.58
$24.80
52-Wochen-Spanne:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.76 | 134.18B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
724.54 | 640.60B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.71 | 428.03B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
220.61 | 386.06B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
123.65 | 236.62B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
78.56 | 193.83B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer (PFE) Doubles Down on Obesity Market—But Will It Pay Off? - MSN
Pfizer Inc. (PFE): A Bull Case Theory - Yahoo
Why Pfizer's Post-COVID Future Looks Brighter Than Ever - Yahoo Finance
Down 55%, Should You Buy the Dip on Pfizer? - AOL.com
Sonora Investment Management Group LLC Has $10.90 Million Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Acquired by Fort Washington Investment Advisors Inc. OH - MarketBeat
Stockman Wealth Management Inc. Buys 30,849 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer’s Bold GLP‑1 Comeback, Dividend Safe For Now (NYSE:PFE) - Seeking Alpha
Kendall Capital Management Makes New $422,000 Investment in Pfizer Inc. $PFE - MarketBeat
Kathmere Capital Management LLC Purchases 16,724 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer: A Reluctant Upgrade To Hold (NYSE:PFE) - Seeking Alpha
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Should You Reconsider Pfizer as Shares Fall After Latest Drug Pipeline Setback? - simplywall.st
Pfizer (PFE) to Acquire Metsera in $4.9 Billion Deal - GuruFocus
Key facts: President Trump plans a 100% tariff on branded drugs, including Pfizer's, unless firms set up U.S. manufacturing plants to protect local producers from foreign imports. - TradingView
Key deals this week: STAAR Surgical, Pfizer, DB Insurance, Strive, Rocket Lab and more (PFE:NYSE) - Seeking Alpha
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet? - The Globe and Mail
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet? - The Motley Fool
Pfizer’s GLP-1 acquisition; Trump’s tariff threat; Scholar Rock gets a CRL; and more - Endpoints News
State of Alaska Department of Revenue Has $18.70 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why. - Barron's
Pfizer is Locking in New Growth Through a New Acquisition - MarketBeat
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock? - MSN
Pfizer Faces Court Over Depo-Provera Brain Tumor Claims - Benzinga
Pfizer just made a quiet move that could rewrite the obesity drug race - TheStreet
Trump Pharma Plan Looks Like Reprieve for Many Drugmakers - Yahoo Finance
Jim Cramer Discusses Sentiment Surrounding Pfizer (PFE) - MSN
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict - ts2.tech
Dakota Wealth Management Reduces Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Maridea Wealth Management LLC Has $233,000 Stake in Pfizer Inc. $PFE - MarketBeat
14,681 Shares in Pfizer Inc. $PFE Acquired by FCG Investment Co - MarketBeat
New Insight Wealth Advisors Acquires 31,696 Shares of Pfizer Inc. $PFE - MarketBeat
Meyer Handelman Co. Sells 11,350 Shares of Pfizer Inc. $PFE - MarketBeat
Eli Lilly, Merck, Pfizer Stocks Rise After Trump Unveils Pharma Tariffs - The Wall Street Journal
Pfizer (PFE) Dips More Than Broader Market: What You Should Know - sharewise.com
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer (NYSE:PFE) Trading Down 2%Should You Sell? - MarketBeat
Pfizer: Buy The Pharma Giant Following The Metsera Deal (NYSE:PFE) - Seeking Alpha
Rx Rundown: Pfizer, Genetix Biotherapeutics, Sanofi and more - Medical Marketing and Media
5.6x Brain Tumor Risk: Pfizer's Depo-Provera Contraceptive Faces 1,300 Lawsuits as New Studies Confirm Danger - Stock Titan
Hearing Against Pfizer Set For 29 September In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio - The Joplin Globe
Pfizer: Invest For The Yield, Not The Weight-Loss Drug Chase (NYSE:PFE) - Seeking Alpha
Pfizer-backed biotech readies expansion after trial success - The Business Journals
Pfizer, BioNTech Challenge GSK Patents Over Vaccine Tech - Law360
Can a multibillion-dollar deal put Pfizer in the obesity big leagues? - PharmaVoice
November 7th Options Now Available For Pfizer (PFE) - Nasdaq
Does This Acquisition Make Pfizer Stock a Great Buy? - Nasdaq
Geriatric Medicines Market Set for Dynamic Growth with Key - openPR.com
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025 - BioSpace
Pfizer to showcase cancer drug data at ESMO Congress 2025 By Investing.com - Investing.com Canada
Essex Financial Services Inc. Purchases 29,086 Shares of Pfizer Inc. $PFE - MarketBeat
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.00%
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):